Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Karolinska Institutet Holding AB (KIHAB) is a venture capital firm established in 1995 by Karolinska Institutet (KI), Sweden's foremost medical university. Located in Solna, Sweden, KIHAB serves as a critical technology transfer vehicle in Europe, managing the commercialization infrastructure of KI. The firm operates through two wholly-owned subsidiaries: KI Innovations, which focuses on early-stage idea development and seed investments, and KI Science Park, a collaborative hub for innovation in the life sciences sector.
Since its inception, KIHAB has evaluated over 1,500 research-based ideas, facilitating the transition from academic concepts to commercial products. The organization is recognized as one of the most significant university tech-transfer vehicles in Europe, particularly in the life sciences domain. KIHAB's unique model connects academia directly to innovation companies, holding companies, and investment firms, thereby streamlining the commercialization process.
Karolinska Institutet Holding specializes in investments related to Life Science and Medical Technology. The firm targets various stages of development, including pre-seed, seed, Series A, Series B, Series C, and growth equity. KIHAB primarily invests in biotech, healthcare, medical devices, and diagnostics sectors, focusing on innovations that emerge from both Swedish and other Nordic universities. This investment strategy emphasizes the professional evaluation, development, and commercialization of research ideas, bridging the gap between academic research and market-ready solutions.
Investment checks are typically small, aligning with the university tech-transfer model, although specific amounts are not disclosed. KIHAB's pipeline is supported by government funding, including a SEK 29 million grant from Vinnova for continued incubator operations from 2025 to 2029. The firm seeks to support researchers and students in building companies based on intellectual property developed at KI, thereby fostering a strong connection between academia and entrepreneurship.
Karolinska Institutet Holding's portfolio includes five notable companies, each contributing to advancements in life sciences:
These companies exemplify KIHAB's commitment to supporting innovative solutions in the healthcare and biotechnology sectors.
Magnus Persson: Magnus serves as a key figure at Karolinska Institutet Holding, bringing extensive experience in venture capital and life sciences. His background includes significant roles in various biotech firms, where he has led numerous successful investments.
Jonny Greinsmark: Jonny is involved in the operational aspects of KIHAB, focusing on supporting portfolio companies. His expertise lies in business development and strategic planning within the life sciences sector.
Mari Lindblom: Mari plays a crucial role in evaluating investment opportunities and managing relationships with academic institutions. Her background includes a strong foundation in research and commercialization strategies.
To pitch to Karolinska Institutet Holding, founders should reach out via email at info@kiholding.se. It is essential to include a comprehensive deck that outlines the business model, market opportunity, and the innovation's connection to life sciences. While specific response time expectations are not provided, founders should anticipate a thorough evaluation process given the firm's focus on academic research.
Warm introductions are beneficial but not mandatory. Founders are encouraged to clearly articulate their value proposition and how their innovations can contribute to advancements in healthcare and biotechnology.
Karolinska Institutet Holding operates several initiatives aimed at fostering innovation in the life sciences. One of the primary programs is KI Innovations, which focuses on the commercialization of research ideas through early-stage support, including coaching and expert networks. This program has been instrumental in developing numerous spinouts from Karolinska Institutet.
Another key initiative is KI Science Park, which serves as a hub for collaboration and networking among life sciences companies. This campus community facilitates partnerships and knowledge exchange, enhancing the innovation ecosystem in the region.
In recent developments, Karolinska Institutet Holding has continued to expand its portfolio with several notable investments. In 2023, KIHAB added Volumeer AB, which specializes in sepsis diagnostics, and SEQURNA, known for RNA preservation reagents. Additionally, Clinsight, focusing on prostate cancer diagnostics standardization, joined the portfolio in the same year.
In 2024, KIHAB invested in AAX BioTech, which is working on antibody improvement technologies. The firm also welcomed Ciprocity in 2025, which develops software for confocal microscopy. These investments highlight KIHAB's ongoing commitment to supporting innovative solutions in the life sciences sector.
What are the investment criteria for Karolinska Institutet Holding?
Karolinska Institutet Holding invests in early-stage companies primarily in the life sciences and medical technology sectors. The firm focuses on innovations that stem from academic research, particularly those developed within Swedish and Nordic universities.
How can founders apply or pitch to KIHAB?
Founders can pitch their ideas by contacting KIHAB directly via email at info@kiholding.se. It is advisable to provide a detailed overview of the business model, market potential, and how the innovation relates to life sciences.
What makes Karolinska Institutet Holding different from other venture capital firms?
KIHAB is unique in its direct connection to Karolinska Institutet, allowing it to leverage academic research and resources effectively. This relationship provides access to a wealth of knowledge and expertise in the life sciences field.
What is the geographic scope of KIHAB's investments?
The firm primarily invests in companies located in Europe, with a strong emphasis on the Nordic region, particularly Sweden.
What is the typical check size for investments?
While specific check sizes are not disclosed, KIHAB typically engages in small initial stakes consistent with university tech-transfer investment practices.
What kind of post-investment involvement does KIHAB have?
Karolinska Institutet Holding provides early-stage support, including coaching, access to expert networks, and potential follow-on investments to help portfolio companies grow and succeed.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.